Lim, Sung Hee
Lee, Keun-Wook
Kim, Jae-Joon
Im, Hyeon-Su
Kim, In-Ho
Han, Hye Sook
Koo, Dong-Hoe
Cho, Jang Ho
Maeng, Chi Hoon
Lee, Min-Young
Lee, Hyo Jin
Kim, Jwa Hoon
Park, Sang Gon
Jung, Joo Young
Shin, Seong-Hoon
Kim, Ki Hyang
Kim, Hyeyeong
Oh, So Yeon
Kang, Minsu
Jung, Minkyu
Rha, Sun Young
Article History
Received: 19 July 2023
Accepted: 6 February 2024
First Online: 23 February 2024
Declarations
:
: This study was approved by the IRBs of each institution as required. The official name of each IRB and approved number is as follows: Institutional Review Boards of Soonchunhyang University Bucheon Hospital (IRB No. 2022-04-014); Seoul National University Bundang Hospital Institutional Review Board (IRB No. SNUBH-B-2205-757-102); Institutional Review Boards of Pusan National University Yangsan Hospital (IRB No. 05-2022-115); Ulsan University Hospital Institutional Review Board (IRB No. 2022-04-033); Institutional Review Board of the Chungbuk National University Hospital, South Korea (IRB No. 2022-04-029); Institutional Review Board of Kangbuk Samsung Hospital (IRB No. 2022-04-030); The Catholic University of Korea, Incheon St. Mary’s Hospital Institutional Review Board (IRB No. OC22RIDI0057); Institutional Review Board of Kyung Hee University Hospital (IRB No. 2022-06-010); Institutional Review Board of Soonchunhyang University Hospital (IRB No. 2022-07-011); Chungnam National University Hospital Institutional Review Board (IRB No. 2022-05-019); Institutional review board of Korea University Anam Hospital (IRB No: 2022AN0396); Chosun University Hospital, Institutional Review Board (IRB No: 2022-06-001); Institutional Review Board of the Hallym University Dongtan Sacred Heart Hospital (IRB No. 2022-05-012); Clinical Trial and Medical Research Ethics Review Committee (IRB No. 2022-05-001); Inje Univerisity Busan Paik Hospital Institutional Review Board (IRB No. 2022-11-035); Severance Hospital Institutional Review Board (IRB No. 4-2022-0522). The requirement of informed consent was waived by the IRBs of all participating institutions due to the retrospective nature of this study. All data were anonymized and de-identified before analysis. This study was registered in the Clinical Trial Registry of Korea (ExternalRef removed: KCT 0007732).
: Not applicable.
: Dr. Lee KW reports grants from Ono pharmaceutical, Merck Sharp and Dohme, AstraZeneca, Merck KGaA, Pfizer, Beigen, Zymeworks, ALX Oncology, LSK BioPharma, Trishula therapeutics, Y-BIOLOGICS, Leap therapeutics (to his institution for conducting clinical trials), personal fees from Ono pharmaceutical, Merck Sharp and Dohme (honorarium), outside the submitted work.